Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Manufacturing of Vaccines - Introduction | 7 | 1 |
| GBI Research Report Guidance | 7 | 1 |
| Manufacturing of Vaccines - Overview of Manufacturing | 8 | 2 |
| Upstream Bioprocessing | 8 | 1 |
| Downstream Bioprocessing | 8 | 1 |
| Methods for Producing Vaccines | 8 | 1 |
| Live Whole Virus Vaccines | 9 | 1 |
| Inactivated Whole Virus Vaccines | 9 | 1 |
| Subunit Vaccines | 9 | 1 |
| Recombinant Virus Vaccines | 9 | 1 |
| Egg-Based Vaccines | 9 | 1 |
| DNA Vaccines | 9 | 1 |
| Current Scenario of the Vaccine Manufacturing Industry | 9 | 1 |
| Manufacturing of Vaccines - Role of Manufacturing in the Vaccine Industry | 10 | 9 |
| Comparison of Manufacturing of Vaccines with Manufacturing of Biologics | 10 | 1 |
| Stakeholders for Manufacturing within the Company | 11 | 1 |
| R&D Division | 11 | 1 |
| Marketing Division | 12 | 1 |
| Sales Division | 12 | 2 |
| Manufacturing Division | 14 | 1 |
| Acquisition Decisions | 14 | 1 |
| Crisis Management | 14 | 1 |
| Responsible for Timely Launch of New Product | 14 | 1 |
| Responsible for Productivity Initiatives | 14 | 1 |
| Design and Technical Support | 15 | 1 |
| Stakeholders for Manufacturing within the Industry | 15 | 1 |
| Raw Material Suppliers | 15 | 1 |
| Essential Characteristics of a Raw Material Supplier | 15 | 1 |
| Packaging Suppliers | 16 | 1 |
| Distributors | 17 | 2 |
| Manufacturing of Vaccines - Vaccine Manufacturing Process | 19 | 26 |
| Overview | 19 | 1 |
| Inactivated Influenza Vaccines | 19 | 1 |
| Live Attenuated Influenza Vaccines | 19 | 1 |
| Pandemic Influenza Vaccines | 19 | 1 |
| Raw Materials | 20 | 1 |
| Process Design | 20 | 1 |
| Sourcing | 20 | 1 |
| Volumes | 20 | 1 |
| Key Positions | 20 | 1 |
| Purchasing Managers | 20 | 1 |
| Supporting Technology | 21 | 1 |
| Bidding Processes | 21 | 1 |
| Assembly | 21 | 1 |
| Inactivated Influenza Vaccine; Egg-Based Manufacture | 21 | 2 |
| Inactivated Influenza Vaccine; Cell Culture-Based Manufacture | 23 | 1 |
| Live Attenuated Influenza Vaccines; Egg-Based Manufacture | 24 | 1 |
| Live Attenuated Influenza Vaccines; Cell-Culture Based Manufacture | 25 | 1 |
| Parvovirus B19 VLP Vaccine | 25 | 1 |
| Process Design | 26 | 1 |
| Cell Line Development | 26 | 1 |
| Mixing | 26 | 1 |
| Scale Up | 26 | 1 |
| Upstream Bioprocessing | 26 | 2 |
| Downstream Bioprocessing | 28 | 2 |
| Quality Check | 30 | 1 |
| Disposal of Waste | 31 | 1 |
| Process Throughput | 31 | 1 |
| Batch Sizes | 31 | 1 |
| Key Positions | 32 | 1 |
| Chief Scientists | 32 | 1 |
| Bioprocess Engineers | 32 | 1 |
| Supporting Technology | 33 | 1 |
| Technologies Used in Manufacturing | 33 | 2 |
| Inventory | 35 | 1 |
| Process Design | 35 | 1 |
| Inventory Management | 35 | 1 |
| Cold Storage Facilities: | 35 | 1 |
| Warehouse Management: | 36 | 1 |
| Stockpiling of Vaccines | 36 | 1 |
| Process Throughput | 37 | 1 |
| Storage Capacities | 37 | 1 |
| Key Positions | 37 | 1 |
| Logistics Managers | 37 | 1 |
| Distribution | 38 | 1 |
| Process Design | 38 | 1 |
| Warehouses and Distribution Centers | 38 | 1 |
| Challenges Faced in Vaccine Manufacturing | 38 | 1 |
| Technological Expertise | 38 | 1 |
| Initial Capital Investment | 39 | 1 |
| Regulatory Challenges | 39 | 1 |
| Unmet Needs in Vaccine Manufacturing | 40 | 1 |
| High Yield Maintenance | 40 | 1 |
| Cost | 41 | 1 |
| Time | 42 | 2 |
| Regulation | 44 | 1 |
| Manufacturing of Vaccines - Vaccine Manufacturing Industry | 45 | 19 |
| Market Characterization of Vaccine Manufacturing Industry | 45 | 1 |
| Overview | 45 | 1 |
| Costs and Timelines of Building a Manufacturing Facility | 45 | 1 |
| Vaccine Production Capacity | 46 | 1 |
| Contract Vaccine Manufacturing Market | 47 | 1 |
| Demand vs Production | 48 | 1 |
| Drivers for Growth of Vaccine Manufacturing | 48 | 1 |
| Threat of Pandemic Influenza | 49 | 1 |
| Increasing Vaccination Coverage for the Vaccines | 49 | 1 |
| Emergence of Novel Production Technologies and Vaccines | 49 | 1 |
| Population Growth | 50 | 1 |
| Economic Reasons | 50 | 1 |
| Barriers for Growth of Vaccine Manufacturing | 50 | 1 |
| Entry Barriers for the Growth of Vaccine Manufacturing: | 50 | 1 |
| Variable Demand | 51 | 1 |
| Limited Production Capacity | 51 | 1 |
| Competitive Assessment | 51 | 1 |
| Market Share | 51 | 1 |
| Profiles of Key Players | 51 | 1 |
| GlaxoSmithKline | 51 | 1 |
| Sanofi Pasteur MSD | 52 | 1 |
| Pfizer | 53 | 1 |
| Merck | 54 | 1 |
| Novartis | 55 | 1 |
| CSL Limited | 56 | 1 |
| Emerging Technologies | 57 | 1 |
| Upstream Bioprocessing | 57 | 1 |
| Emerging Production Systems | 57 | 1 |
| Efficient Filtration Mechanism | 57 | 1 |
| Recombinant Proteins and Enzymes | 57 | 1 |
| Downstream Bioprocessing | 57 | 1 |
| Disposable Reactors | 57 | 1 |
| Filtration Technologies | 58 | 1 |
| Alliances for Vaccine Manufacturing | 59 | 1 |
| Vaccine Facility Construction Alliance | 59 | 1 |
| Contract Manufacturing Alliances | 59 | 1 |
| Strategies in Vaccine Manufacturing | 60 | 1 |
| Manufacturing Strategies | 60 | 1 |
| Acquisition of Facilities | 61 | 1 |
| In-house Facilities | 61 | 1 |
| Outsourcing Strategies | 62 | 1 |
| Selection of CMOs | 62 | 1 |
| Timelines | 63 | 1 |
| CMO-Sponsor Relationship | 63 | 1 |
| Manufacturing of Vaccines - Regulatory Landscape | 64 | 4 |
| The US | 64 | 2 |
| Europe | 66 | 1 |
| Japan | 67 | 1 |
| Manufacturing of Vaccines - Emerging Vaccine Manufacturing Hotspots | 68 | 9 |
| Singapore | 68 | 1 |
| Regulations | 68 | 1 |
| Key Drivers and Restraints | 68 | 1 |
| Drivers | 69 | 1 |
| Regulatory Ease | 69 | 1 |
| Public Interest | 69 | 1 |
| FDI Support | 69 | 1 |
| Institutional Support | 69 | 1 |
| Government Support | 69 | 1 |
| Restraints | 69 | 1 |
| Lack of Technical Expertise | 69 | 1 |
| China | 70 | 1 |
| Regulations | 70 | 1 |
| Key Drivers and Restraints | 71 | 1 |
| Drivers | 72 | 1 |
| Government Support | 72 | 1 |
| Economy Growth Rate | 72 | 1 |
| Intellectual Property (IP) Rights Protection | 72 | 1 |
| Promising Pipeline | 72 | 1 |
| Prospective International Supplier of Raw Material | 72 | 1 |
| Growing Biological Exports | 72 | 1 |
| Restraints | 72 | 1 |
| Biogenerics versus Innovative Discoveries | 72 | 1 |
| Less Penetrated Insurance Industry | 72 | 1 |
| Establishing Quality Management | 73 | 1 |
| India | 74 | 1 |
| Regulations | 74 | 1 |
| Drivers | 75 | 1 |
| Cost Efficient | 75 | 1 |
| Supportive Government | 75 | 1 |
| Scientific Knowledge Pool | 75 | 1 |
| Restraints | 75 | 1 |
| Operational Disruptions | 75 | 1 |
| Unclear Regulations | 75 | 1 |
| Some Other Major Issues | 76 | 1 |
| Manufacturing of Vaccines- Appendix | 77 | 3 |
| Market Definitions | 77 | 1 |
| Abbreviations | 77 | 1 |
| Research Methodology | 77 | 2 |
| Role of Manufacturing in the Vaccine Industry | 78 | 1 |
| The Vaccine Manufacturing Process | 78 | 1 |
| Vaccine Manufacturing Industry | 78 | 1 |
| Regulatory Landscape | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 79 | 1 |
| Sources | 79 | 1 |